US Patent

US8008338 — Ketorolac tromethamine compositions for treating or preventing ocular pain

Method of Use · Assigned to Allergan Inc · Expires 2027-05-24 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions of ketorolac tromethamine at a concentration of less than 0.5% for treating or preventing ocular pain.

USPTO Abstract

Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Drugs covered by this patent

ketorolac-tromethamine (KETOROLAC TROMETHAMINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1181`	—	ketorolac-tromethamine

Patent Metadata

Patent number: US8008338
Jurisdiction: US
Classification: Method of Use
Expires: 2027-05-24
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Allergan Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.